Relationship between SP142 PD‐L1 Expression and 18F‐FDG Uptake in Non‐Small‐Cell Lung Cancer
L Zhao, J Liu, J Shi, H Wang - Contrast Media & Molecular …, 2020 - Wiley Online Library
Objectives. Immune checkpoint blockers constitute the first‐line treatment for advanced non‐
small‐cell lung cancer (NSCLC) with≥ 50% PD‐L1 expression. In NSCLC, PD‐L1 positivity …
small‐cell lung cancer (NSCLC) with≥ 50% PD‐L1 expression. In NSCLC, PD‐L1 positivity …
18F-FDG maximum standard uptake value predicts PD-L1 expression on tumor cells or tumor-infiltrating immune cells in non-small cell lung cancer
B Hu, W Chen, Y Zhang, H Shi, D Cheng… - Annals of Nuclear Medicine, 2020 - Springer
Objectives Programmed cell death-ligand 1 (PD-L1) is expressed on tumor cells (TC) and
tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the …
tumor-infiltrating immune cells (IC). We conducted a retrospective study to investigate the …
Association between 18F-FDG metabolic activity and programmed death ligand-1 (PD-L1) expression using 22C3 immunohistochemistry assays in non-small cell …
L Zhao, J Liu, H Wang, J Shi - The British Journal of Radiology, 2021 - academic.oup.com
Objective: This study sought to investigate the association between 18F-fludeoxyglucose
(18F-FDG) uptake in positron emission tomography/CT (PET/CT) scans and different …
(18F-FDG) uptake in positron emission tomography/CT (PET/CT) scans and different …
Correlation of PD-L1 expression on tumor cell and tumor infiltrating immune cell with 18F-fluorodeoxyglucose uptake on PET/computed tomography in surgically …
B Hu, J Xiao, Y Xiu, Z Fu, H Shi… - Nuclear Medicine …, 2020 - journals.lww.com
Objective The uptake of 18 F-fluorodeoxyglucose (18 F-FDG) PET/computed tomography
(CT) is known to be linked to programmed death ligand 1 (PD-L1) expression on tumor cells …
(CT) is known to be linked to programmed death ligand 1 (PD-L1) expression on tumor cells …
Soluble PD-L1 in NSCLC patients treated with checkpoint inhibitors and its correlation with metabolic parameters
A Castello, S Rossi, L Toschi, L Mansi, E Lopci - Cancers, 2020 - mdpi.com
We investigated the role of soluble PD-L1 (sPD-L1) in non-small cell lung carcinoma
(NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its …
(NSCLC) patients treated with immune checkpoint inhibitors (ICI) and analyzed its …
Predicting programmed death-ligand 1 (PD-L1) expression with fluorine-18 fluorodeoxyglucose ([18F]FDG) positron emission tomography/computed tomography …
DJ Hughes, E Josephides, R O'Shea… - European …, 2024 - Springer
Background Programmed death-ligand 1 (PD-L1) expression is a predictive biomarker for
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
immunotherapy in non-small cell lung cancer (NSCLC). PD-L1 and glucose transporter 1 …
Visualizing dynamic changes in PD-L1 expression in non-small cell lung carcinoma with radiolabeled recombinant human PD-1
Purpose Tumor heterogeneity limits the predictive value of PD-L1 expression and influences
the outcomes of the immunohistochemical assay for therapy-induced changes in PD-L1 …
the outcomes of the immunohistochemical assay for therapy-induced changes in PD-L1 …
Combining PD-L1 expression and standardized uptake values in FDG-PET/CT can predict prognosis in patients with resectable non–small-cell lung cancer
T Miyazawa, K Otsubo, H Sakai, H Kimura… - Cancer …, 2021 - journals.sagepub.com
Background This study aimed to determine the relationship of programmed death-ligand 1
(PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron …
(PD-L1) expression and standardized uptake values in fluorodeoxyglucose–positron …
PD-L1 expression correlation with metabolic parameters of FDG PET/CT and clinicopathological characteristics in non-small cell lung cancer
X Wu, Y Huang, Q Zhao, L Wang, X Song, Y Li… - EJNMMI research, 2020 - Springer
Background Immunotherapy targeting programmed cell death 1 (PD-1) or its ligand 1 (PD-
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
L1) has shown promising results in non-small cell lung cancer (NSCLC) patients. Exploring …
Texture Features of 18F-Fluorodeoxyglucose Positron Emission Tomography for Predicting Programmed Death-Ligand-1 Levels in Non-Small Cell Lung Cancer
T Norikane, M Ishimura, K Mitamura… - Journal of Clinical …, 2024 - mdpi.com
Background: Identifying programmed death-ligand-1 (PD-L1) expression is crucial for
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …
optimizing treatment strategies involving immune checkpoint inhibitors. However, the role of …